Your breakdown of September's macro catalysts, including the potential Fed rate cut and its implications for equities, bonds, and the dollar, is insightful. The current market 'chop' and reversion-to-the-mean dynamics, particularly with $NVDA, $MSFT, and $QQQ pullbacks, highlight the complexities investors face. I'm particularly intrigued by the thematic trades you've identified, such as gold/silver leadership, selective AI beneficiaries, and the cautious stance on small caps. Your options strategies, like collars and put-ratio spreads, offer practical tools for navigating this volatility. Thank you for sharing.
I apreciate the clarity on how the “Economic Modern Family” continues to lead, with sectors like Small Caps (IWM), Retail (XRT), Biotech (IBB), Regional Banks (KRE), and Transportation (IYT) all outperforming SPY even amid short-term corrections. Your point about “the market being as strong as its weakest link” really resonates.
On that note, I'm watching how Semiconductors (SMH)—now underperforming and below the 50-DMA—could evolve from a weak link into a true anchor. If SMH continues to lag, how might that shift the broader sector rotation strategy? Do you see a trigger point—for example, a sustained breakdown below the 50-DMA—or specific macro developments that would flip the narrative from constructive to cautious?
That's the problem. RFK is why we are having children die of measles for the first time in 20 years. Get vaccinated! Politics is politics but science is science. Don't conflate the two.
Latest Comments
AI Smooth Sailing Until The Tide Turns
The Economic Modern Family Outperforms The SPY
Why Oil Prices Don’t Rise To Consistently High Levels
Is It Too Late For Technology Stocks And ETFs?
Trade Tariffs And Geopolitics: The Corporate Roller Coaster
A Smart Way To Grow And Protect Your Retirement Savings
Worrying Indications In Recently Updated World Energy Data
Does America Still Want "Huddled Masses Yearning To Breathe Free"?
When Penny Stocks Can Become Compelling: A Long-Term Buy With CYDY
Implications Of New FDA Leadership In The Biotechnology Industry